Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
← catalyst calendarNCT06531941 · readout in 281 d
Sponsored by MBX Biosciences (industry) · MBX — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
60actual
Sites
23
Countries
Argentina, Turkey (Türkiye), United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-31 | actual | When the study began enrolling |
| Primary completion | 2027-05-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-27 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypoparathyroidism
Interventions
- Drug: 400 µg of MBX 2109 once-weekly by subcutaneous injection
- Drug: 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
Primary outcome
what the primary-completion date above is the date OFTo evaluate the long-term safety and tolerability of weekly MBX 2109 in patients with hypoparathyroidism.
measured 104 weeks
Permalink · MBX's whole pipeline · Catalyst calendar · Every registered study · What changed